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Background: BK polyomavirus infects most of the general population. However, its clinical manifestations are
almost exclusively seen in immunocompromised patients, particularly in kidney and hematopoietic stem cell
transplantation recipients.
Case presentation: A 15-y-old female suffering from common B-cell acute lymphoblastic leukaemia underwent
hematopoietic stem cell transplantation. The patient had reactivation of BKPyV infection and developed an
haemorrhagic cystitis. Three months after transplant, BKPyV viremia and viruria increased and she developed a
severe nephropathy associated to a polyclonal gammopathy with high levels of isolated IgM.
Conclusion: This case report describes a rare and unexpected polyclonal gammopathy developed during a
polyomavirus-associated nephropathy confirmed by immunohistochemical and laboratory analyses.
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BK virus is a polyomavirus (BKPyV) that infects most of
the general population, with seroprevalence rates ap-
proaching 90% by 10 years of age [1]. After primary infec-
tion, the virus remains quiescent in the uroepithelial cells
of kidneys and bladder [2]. Clinical manifestations of
BKPyV infection are almost exclusively seen in immuno-
compromised patients, particularly in those who under-
went kidney or hematopoietic stem cell transplantation
(HSCT) [3,4].
BKPyV reactivation after allogeneic HSCT manifests at
different clinical levels, from asymptomatic viruria to
severe hemorrhagic cystitis (HC) [5]. HC occurs in 5%
to 68% of HSCT recipients [6,7] and can be associated
with significant morbidity and mortality as well as acute
kidney injury by obstruction of the urinary tract due to
the formation of clots.
BKPyV loads can be measured in urine and serum by
quantification of viral DNA with polymerase-chain-
reaction (PCR) test [8].* Correspondence: natalia.maximova@burlo.trieste.it
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unless otherwise stated.In the era of cyclosporine-based immunosuppression,
BKPyV-associated nephropathy had no real clinical signifi-
cance; conversely, the introduction of third gener-
ation immunosuppressors, such as mycophenolate mofetil
(MMF) and tacrolimus (FK-506) into routine management
of transplant patients has led to the current high preva-
lence of BKV-related nephropathy [9]. It has been hypothe-
sized that the diversity in BKPyV reactivation risk between
cyclosporine and FK-506 could in part be due to the differ-
ent antiviral activity of the immunosuppressants. Indeed,
the in vitro antiviral activity of cyclosporine against several
viruses has been demonstrated and its potential effect on
BKPyV explored [10].
It has been shown that the most effective treatment
for BKPyV infection is the reduction of immunosuppres-
sive therapies. Moreover, the addition of the antiviral
agent cidofovir resulted to be helpful in the setting of per-
sistent BK viremia/viruria [11].
This case report shows the development of a rare
polyclonal gammopathy in a HSCT patient with a severe
nephropathy related to an aggressive BK virus disease.
To the best of our knowledge, this is the first report of
a polyclonal gammopathy with lympho-plasma cellstral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Levels of immunoglobulin and blood and urinary













Pre-BMT 320 4 2 1,9×1010 8,3×104
+15 305 3 0 1,8×109 4,4×105
+94 1324 9 15 4,5×1010 1,9×106
+98 1166 8 23 3,0×109 4,2×105
+107 784 6 185 8,0×108 3,7×105
+114 1009 5 304 8,2×107 1,1×105
+125 882 7 393 7,9×107 5,4×103
+127 617 5 269 1,9×108 2,0×104
+134 845 7 189 9,0×107 2,9×104
+142 960 123 180 2,0×107 2,0×105
+150 657 70 248 Not performed Not performed
The table shows IgG, IgM, IgA levels after BKV reactivation, three months after
transplantation in a 15-y-old female suffering from common B-cell acute
lymphoblastic leukemia. IgM levels rise concurrently to BKV viremia and viruria.
*IgG immunoglobulins therapy has been administered.
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BKPyV infection.
Case presentation
A 15-y-old female, suffering from common B-cell acute
lymphoblastic leukemia (ALL) with t(1;19)translocation
was enrolled in a pediatric protocol AIEOP-BFM LLA
2009. After an initial period of remission, she relapsed
during the maintenance phase. Leukemia was consequen-
tely classified as high risk and the patient was treated with
AIEOP REC2003 protocol (Italian pediatric protocol for
ALL relapsed, LLA REC 2003).
Since chemotherapy alone was considered insufficient
and unsafe, bone marrow transplant was performed. The
myeloablative conditioning regimen consisted of fraction-
ated doses of total body irradiation (total dose 12 Gy),
thiotepa (300 mg/m2), cyclophosphamide (1800 mg/m2)
and rabbit antithymocyte globuline (2.5 mg/kg/day), fol-
lowed by infusion of non-manipulated bone marrow
HSC from HLA matched unrelated donor (MUD). Graft-
versus-host disease (GVHD) prophylaxis was performed
with FK-506 and MMF.
Quantitative RT- PCR for BKPyV detection was car-
ried out by using the Euro-RT BKV kit (Eurospital,
Trieste, Italy), which amplifies a region localized in
BKPyV antigen-T gene. Pre-transplant screening for
BKPyV was positive resulting in a viremia of 8.3 × 104 cp/
ml and a viruria 1.9 × 1010 cp/ml, without any clinical
signs of infection. PCR screening tests for other virus
(CMV, EBV, VZV, HSV, HHV-6, Adenovirus, TTV and
JCV) were otherwise negative.
At day +15, neutrophil and platelet engraftment oc-
curred regularly, while lymphocytes were still depleted
with only 0.4% out of 600 total WBC. BKPyV viral blood
load rose up to 4.4 ×105 cp/ml, with a simultaneous mild
decrease of viruria (1.8 × 109 cp/ml). At day +20, the
patient developed haemorrhagic cystitis with a rapid ex-
acerbation of symptoms, ureteric bilateral occlusion and,
consequently, dilatation of calico-pyelic ducts.
At day +24, absolute lymphocyte count was 11 cell/
μl and immunophenotyping showed a predominant
CD3−CD16+/56+ cell population (92%), a very low
percentage of CD3+ T cells (2%), distributed between T
CD3+CD4+ cells (1%) and T CD3+CD8+ cells (1%) and al-
most complete depletion of CD19+ B lymphocytes (0.6%).
Since cidofovir, one of the few drugs with proven efficacy
against BKPyV infection, was unavailable, immunosuppres-
sive therapy was reduced trying to control the disease.
At day +90, two months after immunosuppression
reduction, the patient’s bone marrow biopsy revealed the
presence of 5% B-lymphoblasts, confirming the morpho-
logical relapse of leukemia. On the contrary, there was
complete remission of hemorrhagic cystitis, both BKPyV
viruria and viremia were unchanged and cytometricanalysis showed a severe T and B lymphocyte depletion
(CD3+ 7%, CD19+ 0.1%, absence of CD20, NK cells 91%,
among 786 total lymphocyte/μl), confirming a delay of
bone marrow reconstruction after HSCT.
At day +107, IgM abruptly increased up to 185 mg/dl
(Table 1). Patient’s serum k free light chains measured
160 mg/L (ref. val. 6.7-22.4 mg/L) and λ free light chains
211 mg/L (ref. val. 8.3-27.0 mg/L). The ratio κ/λ was 0.76
(ref. val. 0.31-1.56). Urinary protein electrophoresis showed
mixed proteinuria with predominance of tubular com-
ponents. U-Albumin was 5.09 mg/dL (ref. val. <3), U-alfa1
microglobulin 13.3 mg/dL (ref. val. < 1.2) and U-IgG 0.944
(ref. val. < 0.85). Testing for urinary Bence Jones protein
was positive: k light chains were 5.73 mg/dL and λ light
chains 2.89 mg/dL.
The hypothesis of lymphoproliferation as a conse-
quence of viral infection was taken into account due to
the delay of T-cells reconstruction. Therefore, patient’s
blood samples were analyzed by quantitative PCR for
the presence of EBV, CMV, Adenovirus, HSV-1, HSV-2,
HHV-6, HCV-RNA, HBV-DNA and resulted negative. A
leukemic gammopathy was then suspected. A further
evaluation of blast immunophenotype did not show sig-
nificant differences compared to the onset of the disease.
Moreover, using flow cytometric analysis, leukemic lym-
phoproliferative disease was ruled out since no monoclo-
nal B cells were present and, at the same time, there was
no evidence of plasmacytosis, neither in peripheral blood
nor in bone marrow samples. We also excluded polyclonal
gammopathy caused by autoimmune diseases. All sero-
logical tests resulted negative (antinuclear antibodies,
anti–doublestranded DNA and anti-Smith antibodies,
antineutrophil cytoplasmic antibody, anti–glomerular
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and C4, rheumatoid factor).
After few days the patient’s renal function worsened,
while urinary cytology showed abundant Decoy cells and
big clusters of viral particles in the nucleus of uroepithelial
cells were detected by electron microscopy (Figure 1).
A subsequent kidney biopsy showed a diffuse inflamma-
tory infiltration of the interstitial medullary area mainly
represented by plasma cells associated with edema with-
out signs of immaturity. Tubular epithelium showed
moderate-to-severe atrophy and lesions due to viral cyto-
pathic effect. Confirmation of the identity of the virus was
made with immunohistochemical detection of SV40
T-antigen (Figure 2).
The diagnosis of polyomavirus BK-associated ne-
phropathy (PVAN) was then made and the immuno-
suppression therapy was discontinued. Despite that,
renal function did not improve after the complete
interruption of immunosuppressive therapies and
viremia and IgM levels remained high (Table 1 and
Figure 3).
At day +129 the patient underwent another myeloabla-
tive conditioning in order to perform a second HSCT
from an haploidentical family donor. At day + 135 bone
marrow biopsy showed complete aplasia with no blast
cells. IgM levels slowly decreased, probably due to the
complete depletion of B cells induced by myeloablative
conditioning. Unfortunately, as BKPyV's viremia rose back
to high levels as well as the immunoglobulins and eventu-
ally, three weeks after the second HSCT the patient died.
Death was ascribable to a multiple organ failure due to
chemotherapy toxicity after second transplant condition-
ing regimen, rather than just PVAN.
Conclusion
According to Kidney Disease Improving Global Out-
come Clinical Practice Guidelines for the Care of KidneyFigure 1 Electron micrograph of polyomavirus-infected uroepithelial
shown (1000 nm) (A); the organelles have started to degrade, the cytoplas
500 nm) (B).Transplant Recipients and the guidelines of the American
Society for Transplantation Infectious Disease Commu-
nity of Practice, polymerase chain reaction for BKPyV
DNA in plasma is recommended for screening and diag-
nosis of PVAN. PCR of urine, urinary cytology, and elec-
tron microscopy of urine are also described as optional
examinations. The definitive diagnosis of PVAN should be
sought by demonstrating PV cytopathic changes in renal
tissue, and confirmed by immunohistochemistry or in situ
hybridization (proven PVAN) [12].
During the last three years, BKPyV reactivation has
been weekly monitored in transplant patients of our
Transplant Unit and both viremia and viruria incidence
were in accordance to previous reported values of 20%
and 60%, respectively. On the contrary, it has been no-
ticed that absolute levels of viral blood load were higher
than expected (> 104 copies/ml) leading to the develop-
ment of more significant renal function impairment
compared to those with low viremia, as it has been repor-
ted in the setting of patients who underwent renal trans-
plant [13].
The onset of PVAN in those who underwent HSCT is
rare when compared to BKPyV related haemorrhagic
cystitis, that occurs in up to 25% of patients [4]. There
are only few PVAN reported cases with proven biopsy
following allogeneic HSCT [11,14-16].
The treatment of PVAN is a challenge for physicians.
Since clinical manifestations of BKPyV infection were
evident in our patient and cidofovir was unavailable at
that time, the only possible therapeutic choice was im-
munosuppressive therapy reduction. Moreover, bone
marrow biopsy, performed at day +32, was positive for
minimal residual disease (MRD): in this case, the sus-
pension of the immunosuppressive therapy could allow
an improvement in the T cell-mediated immunity against
the virus with an effect of Graft versus Leukemia (GvL) in
order to limit or retard leukemia relapse. Unfortuntely,cells of the patient. Big clusters of viral particles in the nucleus are
m is homogenous with virus lining the plasma membrane. (Detail,
Figure 2 Abnormal urine cytology with decoy cells. (May-Grundwald-Giemsa) (A); diffuse inflammatory infiltration of interstitial medullary area
represented by lymphocytes, granulocytes and plasma cells with features of epithelial destruction, marked irregularity and hyperchromasia of epithelial
cells nuclei (H&E, 100X) (B); positive immunostaining for SV40 large T-antigen antibody in few nuclei of tubular epithelial cells (100X) (C).
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patient remained T-depleted until second transplantation
was performed.
It is well known that HSCT recipients have a profound
impairment of the immune function during the first four
or five months post-grafting, regardless of the type of graft
(autologous, syngeneic, or allogeneic), the type of under-
lying disease, the conditioning regimen, the type of post-
grafting immunosuppression, the preparative regimen or
the presence of acute GVHD [17]. This leads to a condi-
tion of hypo-immunoglobulinemia that could require also
immunoglobulin replacement therapy. Thus, the develop-
ment and maturation of B cells can be significantly altered
in the post-transplant period, especially in the setting of
ongoing immunosuppression or chronic GVHD. Normal
levels are generally reached within 6–12 months.
It has been observed that isolated episodes of increased
levels of IgM or, rarely, IgA in the early post-transplantFigure 3 Values of BKV’s levels in both blood and urine and concomi
chronological subsequence. HC, hemorrhagic cystitis; HSCT, hematopoietic steperiod could happen, even if this is not related to viral in-
fections or other relevant complications. These obser-
vations are confirmed by literature reports on the
development of clonal gammopathies after myeloablative
allogenic or autologous transplantation [18-20] non related
to malignancy, EBV reactivation or autoimmune diseases.
A possible explanation could be the immune post-HSCT
dysregulation, characterized by a delay in the reconstitu-
tion of B- and T-cell lineages [21]. In this case report, the
patient developed hyper-IgM during polyclonal gammo-
pathy. Clonal gammopathy onset related to herpes vi-
ruses (EBV and/or CMV) is well known and potentially
life-threatening in patients who have performed HSCT,
especially if there is a progression to PTLD. Anyway,
there are no reports about the relation between poly-
clonal gammopathy and PVAN. As far as we know,
BKPyV has no lymphoproliferative activity, unlike EBV
or others herpes viruses.tant Immunoglobulins response. Figure also shows critical events in
m cell transplantation; PVAN, polyomavirus BK-associated nephropathy.
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mononuclear, consisting mainly of plasma cells. Focal or
diffuse interstitial aggregates of plasma cells between
tubules has been reported in 50% of index biopsies in
kidney transplants [22]. Moreover, Kemeny et al. showed
that in plasma cell-rich (PR) biopsies, plasma cells pre-
dominantly produce IgM, and that patients with PVAN
have significantly higher serum IgG and IgM activities
than patients without PVAN.
Rhandawa et al. have studied the humoral immune re-
sponse to BK virus infection in renal transplants showing
that among patients with paired serum samples, most of
those with BKPyV viruria or viremia displayed a substan-
tial increase in IgG, IgA and IgM antibodies levels, indi-
cating that transplant recipients are capable of mounting
anamnestic antibody responses to BKPyV [23].
There are no reports concerning the relationship
between PR biopsy in PVAN with mono- or polyclonal
gammopathies, as reported in our case. It is well known
that in HSCT recipients after myeloablative conditioning
and whereas full-donor chimerism has been proven, im-
munoglobulin production totally depends from donor cells.
Considering that in kidney recipients BKPyV serum
antibodies may partly derive from local intragraft produc-
tion and that serum antibody levels can also reflect the in-
duced immunological response in lymphoid organs [13],
we can hypothesize that, in the reported patient, BKPyV
infection could have led to an inflammatory-induced dys-
regulation of the donor primitive plasma cells.
Rarely, in the post-transplant period, there are patho-
logical high levels of immunoglobulins, especially in
patients with complete lymphocyte depletion. Lympho-
proliferative disease due to viral infections as EBV or CMV
must first be suspected. Anyway, our case suggests that in
the presence of renal impairment, BKyV infection should
be evaluated and viral tests for BKPyV viremia and viruria
should be performed especially in those patients in which
BKPyV has not been routinely screened. Indeed, BKPyV
has acquired more and more important roles in HSCT
recipients and this is even more evident after the introduc-
tion of FK-506 and MMF as prophylaxis for GVHD.
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